NSAID usage: Impact of safety data and product withdrawals on prescribing trends

P and T

Volumn 32, Issue 5, 2007, Pages 284-287

  Vogt, Molly T ^a   Fedutes Henderson, Bethany ^b   Duggal, Amit ^c   Ansani, Nicole T ^d   Gillespie, John ^e   Starz, Terence ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Rite Aid   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d PFIZER INC   (United States)

^e BlueCross BlueShield of Western New York   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; VALDECOXIB;

ARTICLE; DRUG MARKETING; DRUG SAFETY; DRUG USE; HEALTH INSURANCE; PRESCRIPTION;

EID: 34250636796     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Verburg K, Maziasz T, Weiner E, et al. COX-2 specific inhibitors: Definition of a new therapeutic concept. Am J Ther 2001;8:49-64.
2. Electronic Orange Book. Available at: www.fda.gov/cder/ob/default.htm. Accessed January 5, 2006.
3. Boyce EG, Takiya L. Nonsteroidal anti-inflammatory drugs: Review of factors guiding formulary selection. Formulary 2000;35:142-168.
4. Vane J, Botting R. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998;104(3A);2S-8S.
5. Wolfe M, Lichtenstein D, Singh G. Medical progress: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888-1899.
6. Singh G, Ramey D. NSAID-induced gastrointestinal complications: The ARAMIS perspective - 1997. J Rheumatol 1998;25(S51):8-16.
7. Schoenfeld P. An evidence-based approach to the gastrointestinal safety profile of COX-2-selective anti-inflammatories. Gastroenterol Clin North Am 2001;30:1027-1045.
8. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. The VIGOR Study Group. N Engl J Med 2000;343:1520-1528.
9. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. JAMA 2000;284:1247-1255.
10. Ansani N, Fedutes B, Vogt M, et al. Rheumatologic medication utilization in 2003: Prescribing trends and retail sales costs. Arthritis Rheum 2004;50:S81.
11. Fendrick MA. COX-2 inhibitor use after Vioxx: Careful balance or end of the rope? Am J Manag Care 2004;10:740-741.
12. Grosser T, Fries S, Fitzgerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 2006;116:4-15.
13. Psaty BM, Furberg CD. COX-2 inhibitors: Lessons in drug safety. N Engl J Med 2005;352:1133-1135.
14. Drazen JM. COX-2 inhibitors: A lesson in unexpected problems. N Engl J Med 2005;352:1131-1132.
15. Fitzgerald G. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709.
16. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:1068-1073.
17. Ray WA, Stein MC, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-1073.
18. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163:481-486.
19. Graham DJ, Campen D, Hui R. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 2005;365:475-481.
20. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: A population study of elderly adults. Ann Intern Med 2005;142:481-489.
21. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102.
22. Merck announces voluntary worldwide withdrawal of Vioxx. Data on file. Whitehouse Station, NJ: Merck & Co; September 30, 2004. Available at: www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp. Accessed January 2, 2005.
23. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-1091.
24. Bextra (valdecoxib tablets), package insert. New York: Pfizer Inc.; November 2004.
25. Drug Safety and Risk Management Advisory Committee, joint meeting. February 16-18, 2005. Available at: www.fda.gov/ohrms/dockets/ac/cder05. html#ArthritisDrugs.
26. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-884.
27. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-895.
28. FDA. Statement on naproxen. December 20, 2005. Available at: www.fda.gov/bbs/topics/news/2004/NEW01148.html. Accessed December 21, 2005.
29. COX-2 selective (includes Bextra, Celebrex, and Vioxx) and nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). Available at: www.fda.gov/cder/drug/infopage/cox2/default.htm. Accessed January 5, 2006.
30. Rodriguez LAG, Gonzalez-Perez A. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med 2005;3(17):1-6.
31. FDA memo, April 6, 2005. Available at: www.fda.gov/cder/drug/infopage/ COX2/NSAIDdecisionMemo.pdf.